A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
Clin Cancer Res
; 17(21): 6831-9, 2011 Nov 01.
Article
en En
| MEDLINE
| ID: mdl-21908572
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Benzamidas
/
Proteínas HSP90 de Choque Térmico
/
Indazoles
/
Linfoma
/
Neoplasias
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2011
Tipo del documento:
Article